Bristol-Myers drops Hepatitis C dual regimen in U.S.
October 07, 2014 at 11:15 AM EDT
Company will not pursue FDA approval amid ‘rapidly evolving’ treatment landscape.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.